Daniel Kennedy

Daniel Kennedy is an accomplished professional in the biotechnology and pharmaceutical industries, currently serving as Vice President of Business Development and Treasurer at Immunocore since May 2020, where the focus is on transformative medicines for unmet medical needs. Prior to this role, Daniel held the position of Business Development and Alliance Management Lead at Achillion Pharmaceuticals, which was acquired by Alexion for $930 million. Daniel's extensive experience at GSK from 2001 to 2018 included leadership in corporate development, strategic pricing, and marketing, driving significant transactions and pricing strategies for various therapeutic areas. Earlier career roles include positions at Schering Plough and PAREXEL, complemented by an MBA from NYU Stern School of Business and a BS in Economics from Fairleigh Dickinson University.